Macrocyclic Complexes of Alpha-Emitters for Stable Targeted Radiotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current macrocyclic complexes of radionuclides used in targeted radiotherapy suffer from instability, particularly with larger isotopes like actinium, radium, bismuth, and lead, leading to dissociation and reduced selectivity for targeted tissue, resulting in toxicity to non-targeted tissues.
Innovation Solution
Development of new macrocyclic complexes that are more stable and can complex with alpha-emitting radionuclides at room temperature, allowing for targeted cancer therapy with reduced toxicity to non-targeted tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current macrocyclic complexes are used with larger isotopes like actinium, radium, bismuth, and lead, then the radiotherapy treatment can be performed, but the complexes become unstable leading to dissociation and toxicity to non-targeted tissues
Solution Approach 1:
The patent modifies the macrocyclic ligand structure by changing parameters such as ring size, number of donor atoms, and spatial configuration to create new macrocyclic complexes with improved stability constants. These structural parameter changes enable the complexes to maintain stability with larger radionuclides, preventing dissociation and reducing toxicity to non-targeted tissues.
Solution Approach 2:
The patent creates composite macrocyclic ligand structures combining multiple donor atoms (nitrogen, oxygen, sulfur) in specific arrangements within the macrocyclic ring. This composite structure provides enhanced coordination capability and stability for binding radionuclides, particularly larger ones like actinium and bismuth, thereby preventing complex dissociation and reducing off-target toxicity.
2Measurement precision
If conventional macrocyclic complexes are used, then the targeting function can be achieved, but selectivity for targeted tissue is reduced due to dissociation
Solution Approach 1:
The patent optimizes macrocyclic ligand parameters including ring size, donor atom types and positions, and overall molecular geometry to achieve optimal stability constants. These parameter changes ensure the complexes remain intact during circulation and targeting, maintaining high selectivity for targeted tissues by preventing premature dissociation of the radionuclide.
3Reliability
If new macrocyclic complexes are developed for alpha-emitting radionuclides, then enhanced targeting and reduced toxicity can be achieved, but the complexity of complex development increases
Solution Approach 1:
The patent systematically varies macrocyclic ligand parameters (ring size, donor atoms, substituent positions) to identify optimal structures for alpha-emitting radionuclides. This parameter optimization approach, while requiring extensive development, ultimately yields complexes with proven high stability and therapeutic efficacy, reducing off-target toxicity and improving overall treatment reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new complexes provide enhanced targeting of cancer cells with alpha-emitting radionuclides, minimizing toxicity to non-targeted tissues and improving therapeutic efficacy.
Implementation Method 1
macrocyclic complexes of alpha-emitting radionuclides
Data Source
AI summary
The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following:or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,or a pharmaceutically acceptable salt thereof,wherein M1 is independently at each occurrence an alpha-emitting radionuclide. Equivalents of such compounds are also disclosed.